11/09/2020
Texte
Après plusieurs hésitations, des études négatives dans les pneumonies liées au SARS et à la grippe, la corticothérapie fait de nouveau l’actualité à l’occasion des SDRA liées au Coronavirus avec un peu d’espoir alors faisons le point !
- Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19. A Randomized Clinical Trial
https://jamanetwork.com/journals/jama/fullarticle/2770276 - Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19
The CoDEX Randomized Clinical Trial
https://jamanetwork.com/journals/jama/fullarticle/2770277 - Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial
https://jamanetwork.com/journals/jama/fullarticle/2770278 - Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
A Meta-analysis
https://jamanetwork.com/journals/jama/fullarticle/2770279